Skip to main content
Top
Published in: AIDS Research and Therapy 1/2015

Open Access 01-12-2015 | Research

Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011

Authors: Jia Liu, Yasong Wu, Wenjie Yang, Xiujuan Xue, Guoqing Sun, Chunhua Liu, Suian Tian, Dingyong Sun, Qian Zhu, Zhe Wang

Published in: AIDS Research and Therapy | Issue 1/2015

Login to get access

Abstract

Background

In Henan, China, first-line antiretroviral treatment (ART) was implemented early in a large number of treatment-experienced patients who were more likely to have a drug resistance. Therefore, we investigated the human immunodeficiency virus (HIV)-1 drug resistance profiles among patients in Henan who experienced virological failure to ART.

Method

A cross-sectional survey was administered in 10 major epidemic cities from May 2010 to October 2011. Adult patients who experienced virological failure (virus load ≥1,000 copies/mL) with >1 year of first-line antiretroviral treatment consented to provide blood for genotype resistance testing. The clinical and demographic data were obtained from the patients’ medical records. Logistic regression analysis was performed to determine the factors associated with ≥1 significant drug resistance mutation.

Results

We included 3,235 patients with integral information and valid genotypic resistance data. The city, age, CD4 counts, virus load, treatment duration, and World Health Organization stage were associated with drug resistance, and 64.76% of patients acquired drug resistance. The nucleoside reverse transcriptase inhibitor (NRTI), non-(N)NRTI, and protease inhibitor resistance mutations were found in 50.26, 63.12, and 1.30% of subjects, respectively. Thymidine analogue mutations, NNRTI and even multidrug resistance complex were quite common in this patient cohort.

Conclusion

Multiple and complex patterns of HIV-1 drug resistance mutations were identified among individuals who experienced virological failure to first-line ART in Henan, China during 2010–2011. Therefore, timely virological monitoring, therapy adjustments, and more varieties of drugs and individualized treatment should be immediately considered in this patient population.
Literature
1.
go back to reference Antiretroviral Therapy Cohort C (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372(9635):293–299. doi:10.1016/S0140-6736(08)61113-7 CrossRef Antiretroviral Therapy Cohort C (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372(9635):293–299. doi:10.​1016/​S0140-6736(08)61113-7 CrossRef
5.
go back to reference WHO (2012) WHO HIV drug resistance report 2012. World Health Organazation, Geneva WHO (2012) WHO HIV drug resistance report 2012. World Health Organazation, Geneva
9.
go back to reference Ma L, Huang J, Xing H, Yuan L, Yu X, Sun J et al (2010) Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B’ strains from former blood donors in central Chinese provinces. AIDS Res Hum Retroviruses 26(9):1007–1013. doi:10.1089/aid.2009.0252 PubMedCrossRef Ma L, Huang J, Xing H, Yuan L, Yu X, Sun J et al (2010) Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B’ strains from former blood donors in central Chinese provinces. AIDS Res Hum Retroviruses 26(9):1007–1013. doi:10.​1089/​aid.​2009.​0252 PubMedCrossRef
12.
go back to reference Zhong P, Pan Q, Ning Z, Xue Y, Gong J, Zhen X et al (2007) Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 23(7):847–856. doi:10.1089/aid.2006.0196 PubMedCrossRef Zhong P, Pan Q, Ning Z, Xue Y, Gong J, Zhen X et al (2007) Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 23(7):847–856. doi:10.​1089/​aid.​2006.​0196 PubMedCrossRef
15.
go back to reference Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D et al (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11(7):516–524. doi:10.1016/S1473-3099(11)70097-4 PubMedCrossRef Zhang F, Dou Z, Ma Y, Zhang Y, Zhao Y, Zhao D et al (2011) Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 11(7):516–524. doi:10.​1016/​S1473-3099(11)70097-4 PubMedCrossRef
18.
go back to reference Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM et al (2006) Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 44(7):2612–2614. doi:10.1128/JCM.00449-06 PubMedCentralPubMedCrossRef Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM et al (2006) Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 44(7):2612–2614. doi:10.​1128/​JCM.​00449-06 PubMedCentralPubMedCrossRef
19.
go back to reference Balzarini J (2004) Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 4(9):921–944PubMedCrossRef Balzarini J (2004) Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr Top Med Chem 4(9):921–944PubMedCrossRef
21.
go back to reference Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10(3):155–166. doi:10.1016/S1473-3099(09)70328-7 PubMedCrossRef Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM (2010) Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 10(3):155–166. doi:10.​1016/​S1473-3099(09)70328-7 PubMedCrossRef
23.
go back to reference Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C et al (2004) Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 72(1):162–165. doi:10.1002/jmv.10550 PubMedCrossRef Marcelin AG, Delaugerre C, Wirden M, Viegas P, Simon A, Katlama C et al (2004) Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 72(1):162–165. doi:10.​1002/​jmv.​10550 PubMedCrossRef
24.
25.
go back to reference Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P et al (2005) Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 10(7):791–802PubMed Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P et al (2005) Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 10(7):791–802PubMed
27.
go back to reference Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC et al (2013) Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis 207(Suppl 2):S70–S77. doi:10.1093/infdis/jit114 PubMedCentralPubMedCrossRef Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC et al (2013) Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis 207(Suppl 2):S70–S77. doi:10.​1093/​infdis/​jit114 PubMedCentralPubMedCrossRef
28.
go back to reference Maeda Y, Venzon DJ, Mitsuya H (1998) Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 177(5):1207–1213PubMedCrossRef Maeda Y, Venzon DJ, Mitsuya H (1998) Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 177(5):1207–1213PubMedCrossRef
29.
go back to reference Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W (2008) Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol 41(4):310–313. doi:10.1016/j.jcv.2007.12.015 PubMedCrossRef Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W (2008) Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol 41(4):310–313. doi:10.​1016/​j.​jcv.​2007.​12.​015 PubMedCrossRef
Metadata
Title
Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010–2011
Authors
Jia Liu
Yasong Wu
Wenjie Yang
Xiujuan Xue
Guoqing Sun
Chunhua Liu
Suian Tian
Dingyong Sun
Qian Zhu
Zhe Wang
Publication date
01-12-2015
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2015
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-015-0062-y

Other articles of this Issue 1/2015

AIDS Research and Therapy 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.